Sebastian Gensior

A Corporate Pastoral in Four Acts By one who has seen the lanyards and despaired. DRAMATIS PERSONAE * CLAIRE DU VAGUE — Moderator. Professional panelist wrangler. Speaks only in pre-approved key messages. * DR. BLAKE THERESE — Systems biologist turned consultant. Confident. Unclear. * LEONTYNE GRIMM — CEO of HelixBioTrust. Appears remotely. Transmits authority in HD

South Korea’s rise from a war-torn nation in the 1950s to a global technological powerhouse is nothing short of extraordinary. However, as we approach 2025 and beyond, the challenge is to ensure that the big bets which fueled past success have not come at the cost of future innovation

Polygenic risk scores (PRS) are the latest oracle in healthcare’s quest to predict fate. The basic idea sounds beguilingly simple: take the tiny genetic influences scattered across the genome and sum them up into one risk number. If one mutation can’t foretell disease, perhaps hundreds of thousands of

“Excess capacity” – not a phrase one expects to hear in a high-growth industry riding on the coattails of pharmaceutical innovation. Yet in the once-overheated world of contract research and manufacturing, signs of a glut are emerging. Europe’s gleaming labs and China’s biotech parks, which expanded feverishly during the

There are few things more sacred in biotech than the sanctity of government grants. At the heart of this cathedral sits the National Institutes of Health (NIH), a $49 billion-a-year colossus that dispenses lifeblood to labs, startups, and research institutions alike. In countless ways, NIH funding is the foundation on

The field of longevity therapeutics has rapidly progressed from animal studies to human clinical trials in recent years. Multiple approaches – from senolytics to gene therapy – are being tested in clinics around the world. Figure 1 illustrates the geographic span of these trials (primarily in the US, with some in Europe,

Introduction A new breed of lab-coat-clad blockchain enthusiasts believes they can reinvent biomedical research. In decentralized science (“DeSci”), clinical trials go virtual, IP gets tokenized, and research is guided by DAO votes instead of boardroom decisions. It sounds radical – like replacing Big Pharma’s hierarchy with a Discord server. As

Why Many Interventions Improve a Biomarker Without Altering the Underlying Condition Surrogate Markers vs True Outcomes Clinical research often relies on surrogate markers – laboratory values or imaging findings that stand in for actual clinical outcomes. Examples include tumor shrinkage or progression-free survival in cancer, blood glucose (HbA1c) levels in diabetes,

The modern pharmaceutical and scientific job market, dear reader, has developed a peculiar affliction—no, not another variant, but something equally transmissible: credentialitis. A creeping malaise in which individuals collect certifications the way Victorians collected venereal diseases: with surprising enthusiasm and an air of scholarly pride. There is, of course,

It is not often that the bounds of acceptable discourse are described in terms of architecture. Yet the Overton Window—a tidy metaphor for the range of ideas considered palatable in public life—has quietly shaped not only politics, but science, finance, and the technological imagination. What is permissible to